检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]贵阳医学院附院超声中心,贵州贵阳550004
出 处:《贵阳医学院学报》2009年第1期50-52,56,共4页Journal of Guiyang Medical College
摘 要:目的:探讨频谱多普勒Tei指数在评价乳腺癌患者阿霉素心脏毒性方面的临床应用价值。方法:102例乳腺癌患者分为3组:A组26例,给予阿霉素累积剂量<300 mg/m2;B组26例,给予阿霉素累积剂量≥300 mg/m2;C组50例,为对照组。对3组患者心脏进行常规超声测量及Tei指数的测定,并记录治疗组心电图及心肌酶的检查结果。结果:A组与C组之间各参数差异无显著性(P>0.05);B组左室射血分数(LVEF)、短轴缩短率(FS)、心室射血时间(ET)明显减低及等容舒张时间(IRT)、ICT/ET、IRT/ET、Tei指数明显增高且与A组、C组差异均有显著性(P<0.05)。心肌酶与Tei指数检测乳腺癌患者阿霉素治疗后心脏毒性的检出率相同(P>0.05)。结论:频谱多普勒Tei指数对乳腺癌患者阿霉素心脏毒性的临床应用有指导价值。Objective: To explore the application value of spectra Doppler Tei index in judgement of adriamycin-induced myocardial toxicity in breast cancer patients when treated with this medicine. Methods: A total of 102 cases of breast cancer patients were divided into three groups: group A (26 cases, received adriamycin 〈 300 mg/m^2) , group B (26 cases, received adriamycin ≥300 mg/m^2) and group C (50 cases, no adriamycin was used). All the patients were checked and the Tei index and conventional eehocardiographic parameters were obtained. Simultaneously, electrocardiogram and myocardial enzyme activities of the patients with chemotherapy were recorded. Results: No significant difference of conventional eehoeardiographic or Tel parameters was found between groups A and C (P 〉 0.05) ; LVEF, FS and ET were conspicuously lower in group B than those in groups A and C (P 〈 0.05); IRT, ICT/ET, IRT/ET and Tei index were significantly higher in group B than those in groups A and C ( P 〈 0.05 ). Tel index detection rates were corresponding with those of myocardial enzyme detection in breast cancer patients with myocardial toxicity caused by adriamycin treatment (P 〈 0. 05). Conclusion: Tei index is valuable in evaluation of adriamycin-induced myocardial toxicity of breast cancer patients treated with the medicine.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117